Lab Reference Library / Estriol (E3) Hormones & Reproductive

Estriol (E3)

E3 · Estriol · 16-alpha-Hydroxyestrone End Metabolite

Reference range, optimal functional medicine levels, and why estriol is the weakest primary estrogen with selective ER-beta activity, how it reflects estrogen metabolism pathway favorability, and its role in vaginal genitourinary syndrome therapy with lower systemic absorption than estradiol.

Estrogen MetaboliteEstrogen Panel

Non-Pregnant WomenBelow 1 ng/mL

2nd Trimester Preg.0.8 to 7.0 ng/mL

PostmenopausalBelow 0.1 ng/mL

Unitsng/mL

← Back to Lab Reference Library

Category: Hormones & Reproductive | Also known as: E3, Estriol, 16-alpha-Hydroxyestrone End Metabolite

1. What This Test Measures

Estriol (E3) is the third primary estrogen in the human body alongside estradiol (E2) and estrone (E1), and is the weakest of the three in terms of classical estrogen receptor binding affinity. In non-pregnant women, estriol is produced primarily as a downstream metabolite of estradiol and estrone through hepatic hydroxylation, with serum levels that are normally very low (below 1 ng/mL). During pregnancy, the picture changes dramatically: the fetoplacental unit becomes the dominant source of estriol, using fetal adrenal and liver 16-alpha-hydroxylation of dehydroepiandrosterone sulfate (DHEA-S) as the substrate. Maternal serum estriol rises throughout pregnancy to levels many times higher than in the non-pregnant state, making it the dominant estrogen of normal pregnancy. This is why unconjugated estriol is one of the three markers in the second-trimester maternal serum triple or quad screen for fetal chromosomal abnormalities: low estriol signals impaired fetoplacental steroidogenesis, as occurs in Down syndrome and other aneuploidies.

Estriol's receptor pharmacology distinguishes it clinically from estradiol. While estradiol activates both ER-alpha and ER-beta with high affinity (ER-alpha drives proliferative responses in breast and uterine tissue; ER-beta has anti-proliferative and neuroprotective effects in many tissues), estriol has relatively greater ER-beta selectivity and lower ER-alpha potency. This receptor profile makes estriol a weaker mitogen for breast and uterine tissue compared to estradiol, and may explain why high estriol levels during pregnancy have historically been associated with reduced long-term breast cancer risk in epidemiological studies. This receptor selectivity is also the pharmacological rationale for using vaginal estriol rather than vaginal estradiol in women with breast cancer history or significant breast cancer risk factors who require treatment for genitourinary syndrome of menopause (GSM).

In functional medicine, serum estriol is measured as part of comprehensive estrogen metabolism assessment, typically alongside estradiol, estrone, and urinary estrogen metabolites (2-hydroxyestrone and 16-alpha-hydroxyestrone). The estriol-to-estrogen ratio (estrogen quotient) and the 2-OH to 16-OH metabolite ratio together characterize whether a patient's estrogen metabolism pattern is protective or potentially proliferative.

2. Reference Range and Interpretation

Clinical State	Estriol Reference Range	Interpretation Notes
Non-pregnant premenopausal	Below 1.0 ng/mL (typically 0.05 to 0.3)	Low is expected; significance is relative to estradiol/estrone ratio and metabolism pattern
Postmenopausal (no HRT)	Below 0.1 ng/mL (often undetectable)	Very low expected; elevation suggests exogenous source or adrenal over-conversion
On vaginal estriol therapy	Variable; ideally below 0.5 ng/mL	Monitor for systemic absorption; should remain low with appropriate vaginal dosing
First trimester pregnancy	0.1 to 1.0 ng/mL	Rising trend confirms fetoplacental function
Second trimester pregnancy	0.8 to 7.0 ng/mL	Used in triple/quad screen; low value raises Down syndrome risk flag
Third trimester pregnancy	5.0 to 27.0 ng/mL	Continues rising; plateau or fall near term warrants obstetric evaluation

Estriol assays vary significantly in sensitivity and cross-reactivity. Immunoassay-based estriol at low non-pregnant concentrations has limited precision; LC-MS/MS provides more accurate measurement in the sub-1 ng/mL range relevant to non-pregnant functional medicine panels. Conjugated vs unconjugated estriol measurements differ; pregnancy screening uses unconjugated estriol specifically as the fetoplacental marker.

3. Estriol and the Estrogen Metabolism Framework

The clinical significance of estriol in non-pregnant women is best understood within the estrogen metabolism pathway framework rather than as an isolated serum value.

Estradiol is metabolized in the liver through two primary hydroxylation pathways. The 2-hydroxylation pathway produces 2-hydroxyestrone (2-OHE1), a weakly estrogenic or even anti-estrogenic metabolite that is considered protective; high 2-hydroxylation relative to 16-hydroxylation is associated with lower breast cancer risk in epidemiological studies. The 16-alpha-hydroxylation pathway produces 16-alpha-hydroxyestrone (16-OHE1), which is then reduced to estriol; this pathway produces more potent estrogenic metabolites with more proliferative activity. The ratio of 2-OHE1 to 16-OHE1 in urine (measured by the DUTCH test or specific urinary hormone metabolite panels) is the most clinically useful assessment of estrogen metabolism favorability. Dietary factors that shift metabolism toward the 2-hydroxylation pathway include cruciferous vegetable indole-3-carbinol and its metabolite DIM (diindolylmethane), omega-3 fatty acids, and achieving healthy body weight. Obesity, chronic inflammation, and specific CYP1B1 genetic variants favor 16-hydroxylation and estriol production.

4. Therapeutic Estriol: Genitourinary Syndrome of Menopause

Mechanism and indication: genitourinary syndrome of menopause (GSM) encompasses vaginal atrophy, dryness, dyspareunia, recurrent urinary tract infections, urinary urgency, and stress incontinence from estrogen deficiency in urogenital tissue; local vaginal estrogen restores the estrogen-sensitive urogenital epithelium; estriol has an established role in European clinical practice and is increasingly used in the US through compounding pharmacies
Formulations: vaginal estriol cream (0.5 to 1mg per application nightly for 2 weeks, then twice weekly for maintenance); vaginal suppositories (0.5mg); pessaries; compounded estriol in various concentrations; the Vagifem equivalent using estriol rather than estradiol; systemic oral estriol is used in some European menopausal hormone therapy protocols
Systemic absorption profile: vaginal estriol is characterized by very low systemic absorption compared to vaginal estradiol, particularly after the initial 2-week loading phase when atrophic tissue has been partially restored; serum estriol monitoring after 4 to 6 weeks of vaginal therapy confirms minimal systemic exposure; values below 0.5 ng/mL are typical with appropriate vaginal dosing
Use in breast cancer survivors: low-dose vaginal estriol does not meaningfully elevate serum estradiol or estrone and does not appear to increase recurrence risk based on available observational data; endorsed by several oncology organizations as acceptable when non-hormonal therapies are inadequate; women on aromatase inhibitors require additional caution and explicit oncology consultation before initiating any vaginal estrogen
Estriol vs estradiol for GSM: estradiol vaginal cream and ring produce faster symptom relief due to higher receptor potency; estriol produces adequate clinical response in most women within 4 to 8 weeks with its more favorable breast tissue safety profile; the choice depends on urgency of symptom relief, individual risk profile, and oncology history

5. Estriol in Bioidentical Hormone Therapy (Bi-Est and Tri-Est)

Bi-Est Formulations

Bi-Est 80/20: 80% estriol and 20% estradiol by weight; the most commonly prescribed systemic bioidentical estrogen formulation in functional medicine; provides physiological estradiol activity alongside a large estriol component; the 80% estriol is based on the relative proportion of estriol to estradiol during peak reproductive years
Bi-Est 50/50: equal estriol and estradiol; used when somewhat stronger estrogenic activity is needed or when the 80/20 ratio provides inadequate symptom control at tolerable total estrogen doses
Monitoring: serum estriol rises measurably on Bi-Est therapy and should be included in hormone monitoring panels; target serum estriol below 1.5 ng/mL on Bi-Est to avoid excessive 16-hydroxylation pathway activation; estradiol and estrone should be tracked simultaneously
Evidence limitations: Bi-Est and Tri-Est formulations are not FDA-approved and lack the long-term safety and efficacy data of conventional HRT; their use requires informed consent and is based on mechanistic reasoning and clinical experience rather than RCT evidence comparable to conventional estradiol therapy

Estriol as a Neuroprotective Agent

Multiple sclerosis research: estriol has demonstrated anti-inflammatory and neuroprotective effects in animal models of experimental autoimmune encephalomyelitis (EAE) and in early human clinical trials in relapsing-remitting MS; ER-beta activation in oligodendrocytes and microglia promotes remyelination and reduces neuroinflammatory signaling; several Phase II trials have demonstrated cognitive and MRI benefit
Mechanism: estriol's ER-beta selectivity drives anti-inflammatory cytokine profiles in CNS immune cells, promotes oligodendrocyte precursor survival and differentiation, and supports myelin repair pathways; these effects are distinct from the ER-alpha-mediated proliferative actions that create breast and uterine safety concerns
Alzheimer's disease research: preclinical and observational data suggest ER-beta agonism may provide neuroprotective effects relevant to Alzheimer's pathology; estriol is under investigation as a candidate neuroprotective hormone in women with mild cognitive impairment
Current clinical status: estriol as a neuroprotective agent remains investigational; it is not a standard clinical recommendation for MS or Alzheimer's prevention outside of research protocols; patients interested in this application should discuss with neurologists familiar with the current trial landscape

6. Supporting Healthy Estriol Metabolism

Estrogen Metabolism Optimization

DIM (diindolylmethane, 100 to 200mg daily): cruciferous vegetable-derived compound that shifts estrogen metabolism toward the 2-hydroxylation pathway and away from 16-alpha-hydroxylation; reduces estriol production relative to protective 2-OHE1 metabolites; evidence across multiple studies for improving the 2-OH to 16-OH urinary ratio
Indole-3-carbinol (300 to 400mg daily): the DIM precursor found in broccoli, cauliflower, Brussels sprouts; requires stomach acid conversion to DIM; supports CYP1A2-mediated 2-hydroxylation over CYP1B1-mediated 16-hydroxylation
Cruciferous vegetable intake: 1 to 2 cups daily of broccoli, cauliflower, cabbage, kale, or Brussels sprouts provides meaningful I3C and DIM precursor; cooking reduces glucosinolate content; raw or lightly steamed preferred for maximum I3C bioavailability
Achieve and maintain healthy body weight: obesity drives 16-alpha-hydroxylation through adipose aromatase and CYP1B1 upregulation; weight normalization shifts estrogen metabolism toward the more protective 2-hydroxylation pathway
Reduce alcohol intake: alcohol impairs CYP1A2-mediated 2-hydroxylation and promotes 16-alpha-hydroxylation; even moderate alcohol consumption measurably shifts the urinary estrogen metabolite ratio toward increased estriol production

Vaginal Estriol Protocol

Standard initiation protocol: 0.5mg estriol cream vaginally nightly for 14 consecutive nights (loading phase to restore atrophic epithelium), followed by 0.5mg twice weekly for ongoing maintenance; most symptoms improve within 4 to 6 weeks; vaginal dryness responds fastest, followed by dyspareunia, then urinary symptoms
Monitoring during vaginal estriol therapy: serum estriol at 6 to 8 weeks of steady maintenance dosing confirms minimal systemic absorption; values above 0.5 ng/mL suggest higher-than-expected systemic exposure; check estradiol and estrone simultaneously to confirm absence of systemic estrogen elevation
Duration of therapy: GSM is a chronic estrogen-deficiency condition that recurs when therapy stops; long-term use is typically required for sustained symptomatic benefit; annual assessment of continued need, lowest effective dose, and symptom status
Non-hormonal adjuncts: high-quality vaginal moisturizers (Replens, hyaluronic acid-based products) used 3 times weekly provide additional tissue hydration; pH-balanced lubricants for intercourse; pelvic floor physical therapy for urgency, incontinence, and dyspareunia components

Supporting Labs and Monitoring

DUTCH Complete test: the most comprehensive assessment of estrogen metabolism; measures estradiol, estrone, estriol, 2-OHE1, 4-OHE1, 16-OHE1, and their methylated forms; provides the full estrogen metabolism picture that serum estriol alone cannot; recommended before and after DIM or I3C supplementation to confirm pathway shift
Estradiol and estrone concurrent measurement: always measure estriol in the context of estradiol and estrone; isolated estriol without the companion estrogens provides incomplete clinical information; the estrogen quotient calculation requires all three values
CYP1A2 and CYP1B1 genetic variants: pharmacogenomic testing of these estrogen-metabolizing CYP enzymes identifies patients with constitutively high 16-alpha-hydroxylation activity who require more aggressive metabolic intervention; available through comprehensive genetic panels
Mammogram and breast density surveillance: high breast density is associated with elevated estrogen exposure and is itself a breast cancer risk factor; annual mammography with density reporting provides ongoing safety surveillance for all women on estrogen-containing hormone therapy including estriol-based protocols

7. Related Lab Tests

Estradiol (E2)Primary Active Estrogen; Estriol Is Its Downstream Metabolite

→

Estrone (E1)Postmenopausal Dominant Estrogen; Shares Metabolic Pathway with Estriol

→

ProgesteroneEstrogenic Balance Partner; Progesterone Deficiency Amplifies Estrogen Effects

→

SHBGEstrogen-Binding Protein Affecting Free Estrogen Availability

→

FSHOvarian Reserve and Menopause Status Companion Marker

→

LHPituitary Gonadotropin Companion to Estriol in Reproductive Hormone Assessment

→

8. Clinical Perspective

Clinical Perspective

Estriol is the estrogen that most practitioners never measure and most patients never hear about, yet it carries important information about how a woman is metabolizing her estrogens and whether her tissue exposure pattern is more or less proliferative. When I see a postmenopausal woman on Bi-Est with a serum estriol of 2.1 ng/mL alongside a 2-OH to 16-OH ratio on the DUTCH test that is heavily shifted toward 16-hydroxylation, I have a picture of someone whose estrogen metabolism is trending in a direction we want to correct, and DIM and cruciferous vegetables become part of the protocol alongside the hormone monitoring. The clinical application I find most compelling and most underutilized is vaginal estriol for genitourinary syndrome in women with breast cancer history. The systemic absorption data is reassuring, the ER-beta selectivity makes theoretical sense as a tissue safety advantage, and the symptom relief from restored vaginal epithelium is meaningful and real. These women have often been told that hormone therapy is categorically off the table for them, and introducing vaginal estriol with appropriate oncology communication often provides relief they thought was no longer an option. That is the kind of evidence-forward nuance that functional medicine brings to hormone management.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

What is estriol and how does it differ from estradiol?

Estriol is the weakest of the three primary estrogens in the human body, with approximately one tenth the potency of estradiol at classical estrogen receptors. It is produced in large quantities by the placenta during pregnancy (making it the dominant estrogen of pregnancy) but is present only in very small amounts in non-pregnant women, primarily as a metabolite of estradiol and estrone. Functionally, estriol has lower agonist activity at ER-alpha (which drives breast and uterine proliferation) and relatively greater activity at ER-beta (which has anti-proliferative and neuroprotective roles). This receptor selectivity is why estriol is considered a weaker mitogenic estrogen with potentially favorable tissue selectivity compared to estradiol.

Why is estriol measured in functional medicine hormone panels?

Estriol is measured primarily as part of the estrogen metabolism assessment alongside estradiol and estrone. In the 2-16-4 hydroxyestrogen pathway framework, estriol is the 16-alpha-hydroxyestrone pathway end product; its relative level compared to 2-hydroxyestrone (the protective pathway metabolite) provides information about estrogen metabolism favorability. High estriol relative to 2-hydroxyestrone may indicate preferential 16-alpha hydroxylation, which is associated with increased estrogenic tissue stimulation. The estrogen quotient (EQ = estriol divided by the sum of estradiol plus estrone) is sometimes used as a marker of relative breast cancer risk, where higher EQ is considered more protective.

What does low estriol mean in non-pregnant women?

In non-pregnant women, estriol is normally very low (below 1 ng/mL) and is not a primary clinical concern as an isolated measurement. Very low estriol in this context simply reflects low 16-alpha-hydroxylation of estradiol, which is actually associated with a more favorable estrogen metabolism pattern (more 2-hydroxylation relative to 16-hydroxylation). The exception is postmenopausal women on hormone therapy: if vaginal estriol cream is being used for genitourinary syndrome of menopause (GSM), serum estriol monitoring confirms adequate local absorption and systemic safety.

How is estriol used therapeutically?

Estriol is used clinically in three contexts. First, compounded vaginal estriol cream or suppositories for genitourinary syndrome of menopause (vaginal dryness, recurrent UTIs, dyspareunia), where its lower systemic absorption compared to estradiol and its ER-beta selectivity make it a preferred option in women with breast cancer history or breast cancer risk concerns. Second, oral or transdermal estriol is used in some bioidentical hormone replacement protocols, though evidence for systemic estriol in menopause symptom management is weaker than for estradiol. Third, estriol is under research as a potential neuroprotective agent for multiple sclerosis, where its ER-beta activity and anti-inflammatory properties in the CNS are being investigated.

Is vaginal estriol safe after breast cancer?

Vaginal estriol at low doses used for genitourinary syndrome of menopause has very low systemic absorption and does not meaningfully raise serum estradiol or estrone levels. Several oncology organizations including ASCO and NAMS consider low-dose vaginal estrogen, including estriol, acceptable in breast cancer survivors when non-hormonal therapies have failed to adequately control GSM symptoms, with appropriate oncologist consultation. Serum estriol monitoring after initiating vaginal estriol therapy confirms whether systemic absorption is occurring at a clinically significant level. Women on aromatase inhibitors require more caution as even small estrogen elevations may compromise efficacy.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

Estriol reflects estrogen metabolism pathway favorability and provides a safer therapeutic option for genitourinary syndrome in women with breast cancer risk concerns.

Estriol is measured as part of a comprehensive estrogen metabolism assessment at The Lamkin Clinic. Schedule a consultation for a complete hormone panel and personalized estrogen therapy evaluation.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.